These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 14581723)

  • 21. [Urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) and its isoenzyme B as a marker of the nephrotoxicity of gentamicin: re-test from an animal model].
    Ali-Miraftab H; Bourbouze R; Bondiou MT; Percheron F
    Pathol Biol (Paris); 1988 Mar; 36(3):240-4. PubMed ID: 3283687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections.
    Rodriguez-Noriega E; Esparza-Ahumada S; Morfin-Otero R
    J Chemother; 1995 Jun; 7 Suppl 2():155-60. PubMed ID: 8622105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aminoglycoside-related nephrotoxicity in the premature newborn.
    Rajchgot P; Prober CG; Soldin S; Perlman M; Good F; Harding E; Klein J; MacLeod S
    Clin Pharmacol Ther; 1984 Mar; 35(3):394-401. PubMed ID: 6365403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary phospholipids excretion in neonates treated with amikacin.
    Ibrahim S; Langhendries JP; Bernard A; Tulkens PM
    Int J Clin Pharmacol Res; 1994; 14(5-6):149-56. PubMed ID: 7672871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloid bodies in the renal tubules of humans: relationship to gentamicin therapy.
    Houghton DC; Campbell-Boswell MV; Bennett WM; Porter GA; Brooks RE
    Clin Nephrol; 1978 Oct; 10(4):140-5. PubMed ID: 719967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary biomarkers in assessing the nephrotoxic potential of gentamicin in solitary kidney patients after 7 days of therapy.
    Gluhovschi G; Gadalean F; Gluhovschi C; Velciov S; Petrica L; Bob F; Bozdog G; Kaycsa A
    Ren Fail; 2014 May; 36(4):534-40. PubMed ID: 24456153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Aminoglycoside-induced nephrotoxicity].
    Fabrizii V; Thalhammer F; Hörl WH
    Wien Klin Wochenschr; 1997 Nov; 109(21):830-5. PubMed ID: 9454436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Urinary N-acetyl-beta-D-glucosaminidase and gamma-glutamyl-transpeptidase activities for evaluation of renal disturbance in patients with multiple myeloma].
    Nishimura K; Kawada M; Suehiro T; Yamano T; Hashimoto K
    Nihon Jinzo Gakkai Shi; 1992 Oct; 34(10):1087-94. PubMed ID: 1363243
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An overview of the safety of isepamicin in adults.
    Blum D
    J Chemother; 1995 Jun; 7 Suppl 2():87-93. PubMed ID: 8622116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Controlled comparison of amikacin and gentamicin.
    Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS
    N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
    Glass S; Plant ND; Spencer DA
    J Cyst Fibros; 2005 Dec; 4(4):221-5. PubMed ID: 16239129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzymuria in aminoglycoside-induced kidney damage. Comparative study of gentamicin, amikacin, sisomicin and netilmicin.
    Palla R; Marchitiello M; Tuoni M; Cirami C; Giovannini L; Bertelli AA; Bertelli A
    Int J Clin Pharmacol Res; 1985; 5(5):351-5. PubMed ID: 2866167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effect of aminoglycosides on excretion of N-acetyl-beta-glucosaminidase.
    Fujita K; Murayama T; Kawamura M; Narita K
    Int J Clin Pharmacol Res; 1987; 7(6):477-80. PubMed ID: 3440638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal function and effect of aminoglycoside therapy during the first ten days of life.
    Giapros VI; Andronikou SK; Cholevas VI; Papadopoulou ZL
    Pediatr Nephrol; 2003 Jan; 18(1):46-52. PubMed ID: 12488990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective role of nifedipine during gentamicin therapy: randomized controlled trial.
    Vlasic-Matas J; Rumboldt Z; Karelovic D
    Croat Med J; 2000 Dec; 41(4):417-22. PubMed ID: 11063766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gentamicin and amikacin nephrotoxicity: comparative study in patients with initially normal renal function].
    Ballesteros J; Northland R; Wolff M
    Rev Med Chil; 1989 Jan; 117(1):10-7. PubMed ID: 2641618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nitrendipine protects against aminoglycoside nephrotoxicity in the rat.
    Lee SM; Pattison ME; Michael UF
    J Cardiovasc Pharmacol; 1987; 9 Suppl 1():S65-9. PubMed ID: 2441188
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Melatonin reduces urinary excretion of N-acetyl-beta-D-glucosaminidase, albumin and renal oxidative markers in diabetic rats.
    Oktem F; Ozguner F; Yilmaz HR; Uz E; Dündar B
    Clin Exp Pharmacol Physiol; 2006; 33(1-2):95-101. PubMed ID: 16445706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.